5-fraction pancreatic SBRT has been reported using a variety of dose constraints for duodenum, remainder of the small bowel, and stomach. The most common is a maximum dose in the ~30 Gy range. In our series from Moffitt we reported low toxicity using V1 cc < 35 Gy and V5 cc < 30 Gy although in...

This question comes up often. Herman JM et al reported their prospective multi-center (Hopkins, Stanford and Memorial) phase II trial investigating the safety of neoadjuvant gemcitabine followed by fractionated SBRT in patients with locally advanced unresectable pancreatic pancreatic adenocarcinoma...